POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma?

Clinical Biochemistry

Volumn 40, Issue 18, 2007, Pages 1437-1439

  Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EARLY PROSTATE CANCER ANTIGEN 2; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR BIOPSY; TUMOR LOCALIZATION;

BIOLOGICAL MARKERS; CARCINOMA; HUMANS; MALE; MASS MEDIA; PROSTATIC NEOPLASMS; QUALITY CONTROL; RESEARCH;

EID: 36348936853     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.09.003     Document Type: Letter

References (22)

1. Leman E.S., Cannon G.W., Trock B.J., Sokoll L.J., Chan D.W., Marigold L., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69 (2007) 714-720
2. Petricoin III E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
3. Diamandis E.P. Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. Clin Chem 49 (2003) 1272-1278
4. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96 (2004) 353-356
5. Diamandis E.P., and van der Merwe D.-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 11 (2005) 963-965
6. Baggerly K.A., Morris J.S., Edmonson S.R., and Coombes K.R. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97 (2005) 307-309
7. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97 (2005) 315-319
8. Petricoin III E., and Liotta L.A. Counterpoint: the vision for a new diagnostic paradigm. Clin Chem 49 (2003) 1276-1278
9. Sorace J.M., and Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4 (2003) 24
10. Karsan A., Eigl B.J., Flibotte S., Gelmon K., Switzer P., Hassell P., et al. Analytical and preanalytical biases in serum proteomic patterns analysis for breast cancer diagnosis. Clin Chem 51 (2005) 1525-1528
11. Banks R.E., Stanley A.J., Cairns D.A., Barrett J.H., Clarke P., Thompson D., et al. Influences of blood sample processing on low-molecular-weight proteomic identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51 (2005) 1637-1649
12. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5 (2005) 142-149
13. Villanueva J., Shaffer D.R., Phillip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116 (2006) 271-284
14. Diamandis E.P., Kulasingam V., and Sardana G. Letter to the editor about differential exoprotease activities confer tumor-specific serum peptidome. J Clin Invest (2006). http://www.jci.org/cgi/eletters/116/1/271#464 [http://www.jci.org/cgi/eletters/116/1/271#464]
15. Diamandis E.P., Christopoulos T.K., and Khosravi M.J. Development of in-house immunoassays. In: Diamandis E.P., and Christopoulos T.K. (Eds). Immunoassay (1996), Academic Press, New York 555-568
16. Diamandis E.P. Prostate-specific antigen: its usefulness in clinical medicine [review]. Trends Endocrinol Metab 9 (1998) 310-316
17. Shulman R. NMR-another cancer-test disappointment. N Engl J Med 322 14 (1990) 1002-1003
18. Diamandis E.P. Quality of the scientific literature: all that glitters is not gold. Clin Biochem 39 (2006) 1109-1111
19. Winter J.M., Brody J.R., and Kern S.E. Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther 5 (2006) 360-370
20. Kern S.E., and Winter J.M. Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 5 (2006) 349-359
21. Brody J.R., and Kern S.E. Stagnation and herd mentality in the biomedical sciences. Cancer Biol Ther 3 (2004) 903-910
22. Leman E.S., Schoen R.E., Weissfeld J.L., Cannon G.W., Sokoll L.J., Chan D.W., et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 67 (2007) 5600-5605